Vera Therapeutics, Inc.
VERA
$21.71
-$0.32-1.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 101.16% | 149.35% | 67.73% | 39.95% | 28.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 83.83% | 80.98% | 128.91% | 69.97% | -0.47% |
| Operating Income | -83.83% | -80.98% | -128.91% | -69.97% | 0.47% |
| Income Before Tax | -82.13% | -69.27% | -131.95% | -67.19% | 5.61% |
| Income Tax Expenses | -- | 0.00% | -- | -- | -- |
| Earnings from Continuing Operations | -82.13% | -69.27% | -131.95% | -67.19% | 5.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -82.13% | -69.27% | -131.95% | -67.19% | 5.61% |
| EBIT | -83.83% | -80.98% | -128.91% | -69.97% | 0.47% |
| EBITDA | -83.62% | -80.80% | -128.86% | -67.10% | -- |
| EPS Basic | -45.82% | -23.98% | -87.42% | -35.24% | 30.25% |
| Normalized Basic EPS | -45.80% | -23.98% | -87.46% | -35.39% | 30.25% |
| EPS Diluted | -45.82% | -23.98% | -87.42% | -35.24% | 30.25% |
| Normalized Diluted EPS | -45.80% | -23.98% | -87.46% | -35.39% | 30.25% |
| Average Basic Shares Outstanding | 24.92% | 36.53% | 23.75% | 23.63% | 35.32% |
| Average Diluted Shares Outstanding | 24.92% | 36.53% | 23.75% | 23.63% | 35.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |